Botox for Pediatric Sleep Bruxism: Case Report and TMD Treatment Insights

Introduction

Ten units of botulinum toxin type A, injected into each masseter muscle of a healthy eight-year-old girl, resolved her sleep bruxism symptoms within a day — according to the first known pediatric case report of its kind, published by researchers at Instituto Malaguti in Brazil. Meanwhile, a study of 609 Brazilian patients with temporomandibular disorders suggests that what you expect from bruxism and jaw-pain treatment may shape outcomes as much as the treatment itself.

How Botulinum Toxin Quiets Overactive Jaw Muscles — Now in a Child

Sleep bruxism — rhythmic grinding or clenching during sleep — affects a substantial share of children, yet evidence-based options for them are scarce. Most pediatric guidance leans on observation, dental guards, and addressing contributing factors, because medications carry risk in growing bodies. The Cureus case report, authored by Mallaguti and colleagues at Instituto Malaguti in Uberaba, Brazil, offers a new data point: 10 units of BTX-A per masseter muscle, delivered at two injection points per side guided by anatomical landmarks and palpation.

The mechanism deserves explanation. BTX-A blocks the release of acetylcholine from nerve terminals at the neuromuscular junction. Without this chemical signal, the masseter — the primary jaw-closing muscle and the engine of most grinding force — cannot fully contract. The result is a partial, temporary chemodenervation: muscle force drops, tooth wear slows, morning jaw pain eases. Notably, the toxin does not touch the central nervous system circuits that generate bruxism, likely tied to brief arousal responses during sleep. Grinding may continue at reduced intensity; the damage and discomfort are what fade.

Symptom resolution appeared the day after treatment and held for roughly two months, consistent with the known duration of BTX-A effect before nerve terminals regenerate. Caveats are real: this is one child, no control condition, and no long-term safety data. The authors themselves call for research on optimal dosing in children. Masseter injections in adults can occasionally cause chewing fatigue or asymmetry, and pediatric dosing is inherently conservative territory.

What 609 Jaw-Pain Patients Reveal About Expectations

A second Brazilian study, led by Coelho and colleagues at the Bauru School of Dentistry, University of São Paulo, examined 609 patients diagnosed with temporomandibular disorders using the DC/TMD criteria — the standard diagnostic framework. The cohort was 78.7% female, mirroring the well-known sex skew in TMD clinics. Each patient completed psychosocial assessments including the Pain Catastrophizing Scale, the Generalized Anxiety Disorder-7 questionnaire, and the Pittsburgh Sleep Quality Index. Researchers then used an AI-guided language analysis, manually validated, to classify patients’ open-ended statements about what they expected from treatment.

Why does this matter for bruxism? Because sleep bruxism is strongly associated with TMD pain, and expectation is not a soft variable. Catastrophizing — the tendency to magnify pain and anticipate the worst — is one of the most consistent predictors of poor outcomes across chronic pain conditions. Anxiety and poor sleep quality feed the same loop: worse sleep predicts more arousal-related motor activity, which is the likely physiological pathway connecting stress, fragmented sleep, and nocturnal grinding. Our earlier coverage of stress and jaw clenching covers this distinction in detail.

What the Evidence Means for Treatment Sequencing

Read together, the two studies sketch a management hierarchy. First-line approaches remain conservative: identifying contributors such as sleep-disordered breathing — the connection between sleep apnea and teeth grinding is well documented — along with sleep hygiene, stress reduction, and protective oral appliances where tooth damage is active. Second-line options for refractory muscle hyperactivity include physical therapy, as we discussed in our piece on physical therapy for sleep bruxism, and now, cautiously, BTX-A — which adult trials support and which this pediatric report extends, tentatively, to children.

The psychological layer is not optional. The São Paulo findings argue that clinicians should assess catastrophizing, anxiety, and sleep quality at intake, because these variables color expectations, and expectations color reported outcomes. A patient who believes nothing will work may underreport improvement and disengage from therapy.

Practical Applications for Patients and Parents

• If you grind loudly and wake with jaw pain or headaches, ask about sleep apnea screening first — treating the airway often reduces grinding more than any dental device.
• For children with severe grinding and tooth damage, BTX-A is emerging as an option, but it remains off-label and evidence is thin; discuss risks with a specialist before pursuing it.
• Manage the beliefs, not just the bite. If you notice catastrophic thinking about jaw pain (“this will never get better”), tell your clinician — psychological support is a legitimate part of TMD care.
• Protect sleep quality deliberately. Poor sleep measured by tools like the Pittsburgh Sleep Quality Index tracks with worse bruxism outcomes; consistent bedtimes and reduced evening arousal help.

Frequently Asked Questions

Is botulinum toxin safe for children with bruxism?

One case report of a healthy eight-year-old showed symptom relief for two months with no adverse effects, but a single case cannot establish safety. Dosing protocols and long-term effects in children still need formal study.

Does botulinum toxin stop grinding permanently?

No. Effects last around two to three months before nerve terminals recover and muscle force returns. Repeat injections are needed, and the toxin weakens muscle consequences rather than curing the underlying behavior.

Why do my expectations about treatment matter?

In a study of 609 TMD patients, psychosocial factors including pain catastrophizing, anxiety, and sleep quality shaped treatment expectations — and expectations influence how patients perceive and report outcomes.

What should I try first for sleep bruxism?

Evidence supports ruling out sleep apnea, improving sleep quality, and using protective dental appliances to limit tooth damage before considering injections or medication.

Conclusion

Sleep bruxism management is maturing into a layered discipline: protect the teeth, treat the airway, address stress and sleep quality, and — for severe muscle hyperactivity — consider botulinum toxin, now with tentative pediatric support. The Brazilian research adds a reminder that the mind belongs in the treatment plan too: expectations, catastrophizing, and sleep quality are measurable variables with measurable consequences. Managing bruxism well means treating the whole patient, jaw and beliefs alike.

Sources:
https://pubmed.ncbi.nlm.nih.gov/41804406/
https://pubmed.ncbi.nlm.nih.gov/41740202/
https://pubmed.ncbi.nlm.nih.gov/41720287/
https://pubmed.ncbi.nlm.nih.gov/41702318/
https://pubmed.ncbi.nlm.nih.gov/41669869/